| Filed On | Filing |
|---|---|
| 07 Mar 2019 |
8-K/A: Departure/Election of Directors or Officers; Compensation
The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract... |
| 09 May 2017 |
8-K/A: Results of Operations and Financial Condition
CORRECTING and REPLACING Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017 |
| 24 Nov 2014 |
8-K/A: Financial Statements and Exhibits
WATERTOWN, Mass., November 24, 2014 — Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today reported finan... |
Loading...